Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis

BACKGROUND: Elexacaftor-tezacaftor-ivacaftor (ETI) has transformed cystic fibrosis (CF) care, but individual responses remain variable. Although longitudinal studies indicate that ETI reshapes lung and gut microbiota, the contribution of direct drug-microbe interactions remains unclear. We used an in vitro pharmacomicrobiomics approach to screen bidirectional interactions between individual cystic fibrosis transmembrane conductance regulator (CFTR) modulators and CF-relevant bacteria from pulmonary and intestinal niches. METHODS: Thirty-five Gram-positive and Gram-negative strains (15 reference strains, 20 pulmonary clinical isolates) were selected according to their frequency in CF lung and gut microbiota. Bacteria were grown in brain-heart infusion or M9 medium with or without elexacaftor, tezacaftor or ivacaftor. Growth was assessed by OD600 and CFU counts, and residual parent-drug concentrations were quantified by validated liquid chromatography-tandem mass spectrometry. Logistic growth models were fitted to OD600 data. RESULTS: Elexacaftor modestly increased growth of Pseudomonas aeruginosa and Escherichia coli reference strains, but not clinical P. aeruginosa isolates, suggesting strain-dependent effects. Ivacaftor inhibited all Staphylococcus aureus strains, including methicillin-resistant S. aureus, and several anaerobic commensals, while leaving P. aeruginosa and E. coli largely unaffected. Tezacaftor had no detectable effect on growth. In sterile media, all three modulators remained relatively stable. In bacteria-exposed cultures, parent-drug concentrations decreased by approximately 60-70%, with several pathogens and commensals showing high-depleting phenotypes. CONCLUSIONS: CFTR modulators and CF-associated microbiota interact bidirectionally in vitro. Elexacaftor and ivacaftor exert compound-, species- and strain-dependent effects on bacterial growth independent of their canonical role in restoring CFTR function, while multiple bacterial species decrease detectable parent-drug concentrations in culture supernatants.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-09-04
DOI
https://doi.org/10.1016/j.biopha.2026.119892
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis

Elena K. Schneider‐Futschik, Yimin Zhu, Pierrick Boulic, Cyril Leven et al.
Biomedicine & Pharmacotherapy
Cystic Fibrosis Research Advances
article

Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis

Elena K. Schneider‐Futschik, Yimin Zhu, Pierrick Boulic, Cyril Leven, Juliana Alcoforado Diniz, Danni Li, Geneviève Héry-Arnaud, Stéphanie Gouriou
article en

Abstract

BACKGROUND: Elexacaftor-tezacaftor-ivacaftor (ETI) has transformed cystic fibrosis (CF) care, but individual responses remain variable. Although longitudinal studies indicate that ETI reshapes lung and gut microbiota, the contribution of direct drug-microbe interactions remains unclear. We used an in vitro pharmacomicrobiomics approach to screen bidirectional interactions between individual cystic fibrosis transmembrane conductance regulator (CFTR) modulators and CF-relevant bacteria from pulmonary and intestinal niches. METHODS: Thirty-five Gram-positive and Gram-negative strains (15 reference strains, 20 pulmonary clinical isolates) were selected according to their frequency in CF lung and gut microbiota. Bacteria were grown in brain-heart infusion or M9 medium with or without elexacaftor, tezacaftor or ivacaftor. Growth was assessed by OD600 and CFU counts, and residual parent-drug concentrations were quantified by validated liquid chromatography-tandem mass spectrometry. Logistic growth models were fitted to OD600 data. RESULTS: Elexacaftor modestly increased growth of Pseudomonas aeruginosa and Escherichia coli reference strains, but not clinical P. aeruginosa isolates, suggesting strain-dependent effects. Ivacaftor inhibited all Staphylococcus aureus strains, including methicillin-resistant S. aureus, and several anaerobic commensals, while leaving P. aeruginosa and E. coli largely unaffected. Tezacaftor had no detectable effect on growth. In sterile media, all three modulators remained relatively stable. In bacteria-exposed cultures, parent-drug concentrations decreased by approximately 60-70%, with several pathogens and commensals showing high-depleting phenotypes. CONCLUSIONS: CFTR modulators and CF-associated microbiota interact bidirectionally in vitro. Elexacaftor and ivacaftor exert compound-, species- and strain-dependent effects on bacterial growth independent of their canonical role in restoring CFTR function, while multiple bacterial species decrease detectable parent-drug concentrations in culture supernatants.

Biomedicine & PharmacotherapyVol. 203
Inserm (FR), Université de Bretagne Occidentale (FR), The University of Melbourne (AU), École nationale d'ingénieurs de Brest (FR), Centre Hospitalier Régional Universitaire de Brest (FR)
Association Vaincre la Mucoviscidose
Zero hunger
Openalex Percentile: Top 11%
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.